The hallmarks and classification of cellular senescence in cancer are summarized, major cell death modalities are outlined, cross-regulatory networks linking senescence and death are discussed, and emerging therapeutic strategies that target these interconnected processes for cancer treatment are highlighted.
Abstract
Cellular senescence and regulated cell death represent two fundamental but intricately connected biological programs that govern tumor cell fate. Cellular senescence can suppress tumor growth by inducing stable cell-cycle arrest and promoting immune clearance, but persistent senescent cells may also drive tumor progression through the senescence-associated secretory phenotype (SASP). Concurrently, multiple modalities of regulated cell death—including apoptosis, ferroptosis, cuproptosis, necroptosis, pyroptosis, parthanatos, and autophagy-dependent cell death—have emerged as critical determinants of therapeutic response. The crosstalk between senescence and cell death is orchestrated by key molecular hubs including p53, mitochondria, autophagy machinery, and epigenetic regulators. In this review, we summarize the hallmarks and classification of cellular senescence in cancer, outline major cell death modalities, discuss the cross-regulatory networks linking senescence and death, and highlight emerging therapeutic strategies that target these interconnected processes for cancer treatment.
Overall, current data support a context-dependent role for persistent senescence in treatment resistance, but do not establish TIS as a universal or independent cause of therapeutic failure.
The geroncogenic shift framework provides a conceptual basis for linking aging biology with tumor evolution and for developing more selective approaches to senescence-directed therapy.
Yu-Bo Zhang, Yue Han, Pin-Zhi Hou et al.· Frontiers in Pharmacology· 0 citations
Cellular senescence, a stable state of cell cycle arrest triggered by intrinsic and extrinsic stressors, has emerged as a pivotal regulator of tumor immunity and therapeutic resistance. Senescent cells exhibit pronounced temporal heterogeneity in immune modulation. Early-stage senescence enhances antitumor immunity by...
Si-Yu Chen, Jing Su, Ao-Jia Jin et al.· Journal of Cancer Metastasis...· 0 citations
Cancer cell plasticity, the ability of tumor cells to switch between distinct cellular states, has emerged as a key mechanism driving tumor progression, metastasis and therapy resistance. Cancer cells exploit diverse plasticity mechanisms, including dedifferentiation, transdifferentiation, epithelial-mesenchymal transi...
Yoojeong Seo, Jin-Ho Jang, Jae-Il Park· Experimental and Molecular M...· 0 citations
Simple Summary Cells exposed to damaging or stressful conditions can enter senescence, a stable state in which they stop dividing and undergo functional changes, including the production of secreted factors known as the senescence-associated secretory phenotype. Senescence can protect against tumor formation by prevent...
J. M. García-Heredia· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.